Apatinib is a multitarget tyrosine kinase inhibitor marketed in China for the treatment of
advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used …

Background Recently, a variety of clinical trials have shown that apatinib, a small-molecule
anti-angiogenic drug, exerts promising inhibitory effects on multiple solid tumors, including …

The mortality of lung cancer is surprising, even though the development of different
treatments and diagnosis methods. Besides, non-small cell lung cancer (NSCLC) takes a …

Background Although targeted agents have been gradually applied in the treatment of
HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic …

The efficacy of apatinib has been confirmed in the treatment of solid tumors, including non-
small-cell lung cancer (NSCLC). However, the direct functional mechanisms of tumor …

Purpose: In early-stage, EGFR mutation–positive (EGFR-M+) non–small cell lung cancer
(NSCLC), surgery remains the primary treatment, without personalized adjuvant treatments …

Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …

Although anti-angiogenic agents have been of limited use in the treatment of non-small cell
lung cancer (NSCLC) until recently, further roles for the use of angiogenesis inhibition have …

Simple Summary The presence of an EGFR activating mutation in tumors of non-small-cell
lung cancer patients enables effective targeted therapy towards EGFR. Studies that describe …

Lung cancer is the leading cause of cancer-related deaths worldwide. As the most prevalent
molecular mutation subtypes in non-small cell lung cancer (NSCLC), EGFR-TKIs are …